News releases from Quantum Leap Healthcare Collaborative
Aerpio and Quantum Leap Announce First Patients Dosed with Razuprotafib in the I-SPY COVID Trial to Treat ARDS in Critically-ill COVID-19 Patients
September 01, 2020
Aerpio Pharmaceuticals, Inc. ("Aerpio") (Nasdaq: ARPO) and Quantum Leap Healthcare Collaborative™ (Quantum Leap) announced today dosing of the first patient with razuprotafib in the I-SPY COVID Trial...
Members Of The COVID R&D Alliance And Quantum Leap Healthcare Collaborative Enroll First Patients In I-SPY COVID Trial
August 03, 2020
- I-SPY COVID will evaluate the impact of cenicriviroc, Otezla®, and Firazyr® on inflammatory response in COVID-19 patients
Quantum Leap Healthcare Collaborative Announces the Selection of Byondis' SYD985 in the I-SPY 2 TRIAL for Stage 2/3, High-Risk Breast Cancer
July 07, 2020
Quantum Leap Healthcare Collaborative™ (Quantum Leap) announced today the initiation of an investigational treatment arm with Byondis' [vic-]trastuzumab duocarmazine (SYD985) in the ongoing I-SPY 2...
Quantum Leap Healthcare Collaborative Announces the Selection of Sanofi's SAR439859 as the oral SERD Backbone Agent in the Endocrine Optimization Pilot Study of the I-SPY 2 TRIAL for Clinically High R
June 08, 2020
Quantum Leap Healthcare Collaborative™ (Quantum Leap) announced today an evaluation of SAR439859, an oral estrogen receptor degrader (SERD) in a new I-SPY 2 study arm targeting patients with newly...
Aerpio Pharmaceuticals, Inc. and Quantum Leap Healthcare Collaborative Announce the Selection of Razuprotafib for Evaluation in the I-SPY COVID Trial for the Treatment of Acute Respiratory Distress Sy
May 27, 2020
Aerpio Pharmaceuticals, Inc. ("Aerpio") (Nasdaq: ARPO) and Quantum Leap Healthcare Collaborative™ (Quantum Leap) announced today an agreement has been reached to evaluate razuprotafib in a new...
Quantum Leap Healthcare's I-SPY 2 Investigators, ARDS Experts and COVID R&D Consortium Unite to Bring Success from the I-SPY Adaptive Platform Clinical Trial to COVID-19 ARDS ICU Patients
April 28, 2020
Quantum Leap Healthcare Collaborative (QLHC), a non-profit organization focused on uniting patient care and research, and sponsor of the adaptive platform I-SPY 2 Trial™, announced today a unique...
I-SPY2 TRIAL Demonstrates Significant Improvement in pCR with Durvalumab and Olaparib with Paclitaxel, (Compared to Chemotherapy Alone) in Women with Stage II/III High-Risk, HER2-Negative Breast Cance
April 27, 2020
I-SPY 2 TRIAL researchers presented results on April 27 at the clinical trial plenary session of the American Association for Cancer Research (AACR) 2020 annual meeting, which showed that adding the...
Quantum Leap Healthcare Collaborative and G1 Therapeutics Announce the Selection of Trilaciclib in the I-SPY 2 TRIAL for Breast Cancer
January 14, 2020
Quantum Leap Healthcare Collaborative™ and G1 Therapeutics, Inc. (Nasdaq: GTHX) announced today a collaboration to evaluate trilaciclib, an investigational therapy designed to improve outcomes for...
Laura Esserman, MD, Co-founder of Quantum Leap Healthcare Collaborative and Professor at UCSF, will speak at the TIME 100 Health Summit
October 16, 2019
Quantum Leap Healthcare Collaborative is pleased to announce that co-founder Dr. Laura Esserman will be among the speakers of the first-ever TIME 100 Health Summit, which will convene individuals from...
KEYTRUDA's Recent Success in Triple-Negative Breast Cancer Validates I-SPY 2 Adaptive Platform Approach to Phase II Clinical Trials
August 07, 2019
Quantum Leap Healthcare Collaborative (QLHC) joins Merck in acknowledging the promising data from the KEYNOTE-522 trial. Merck recently announced that the Phase 3 KEYNOTE-522 trial met a primary...
I-SPY 2, an Innovative Clinical Trial Model that is Revolutionizing the Treatment of Early Stage, High-Risk Breast Cancer
September 12, 2018
The Impact Of The Revolutionary I-SPY 2 TRIAL On Early Stage, High-Risk Breast Cancer Treatment: The Future Of Clinical Trials
September 07, 2018
Quantum Leap Healthcare Collaborative™, sponsor of the I-SPY 2 TRIAL™, will host a press conference on September 12, 2018 at the National Press Club to update the media, patients, and the public on...
Quantum Leap Healthcare Collaborative Announces AstraZeneca's Olaparib And Durvalumab? For The I-SPY 2 Trial For Breast Cancer
September 06, 2018
Quantum Leap Healthcare Collaborative™ (QLHC) announced today that a new randomized, investigational treatment arm for the I-SPY 2 TRIAL™ includes the study of olaparib and durvalumab, two agents from...